Incyte Corp Stock Price, News & Analysis

Specialised Therapeutics (ST) has expanded its partnership with Incyte to distribute two additional oncology therapies - axatilimab (Niktimvo) and retifanlimab (Zynyz) - in Australia, New Zealand, and Singapore. These medicines join the existing portfolio of Minjuvi and Pemazyre. Axatilimab, approved by FDA in August 2024, treats chronic graft-versus-host disease in patients who've had at least two prior treatments. Retifanlimab is approved for treating squamous cell carcinoma of the anal canal and Merkel cell carcinoma, with Australia having the highest MCC incidence globally. Under the agreement, Incyte will handle development and manufacturing, while ST will manage regulatory affairs, distribution, and local marketing. ST plans to submit both drugs for regulatory and reimbursement approval in 2025.

Incyte (INCY) has granted restricted stock unit awards (RSUs) totaling 16,550 shares to 19 new employees under its 2024 Inducement Stock Incentive Plan. The grants, effective June 2, 2025, were approved by the company's compensation committee as an inducement for new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting annually, contingent on continued employment with the company.

Incyte (INCY) announced multiple presentations at the 2025 European Hematology Association Congress in Milan, featuring late-breaking data for INCA033989, their novel mutCALR-directed monoclonal antibody for essential thrombocythemia (ET). The presentations include data from their hematology/oncology portfolio, with a key focus on INCA033989's potential as a disease-modifying treatment for myeloproliferative neoplasms. The congress will feature presentations on various programs including INCA035784, ruxolitinib, tafasitamab, axatilimab, INCB057643, and ponatinib. Incyte will host an analyst and investor event on June 15, 2025, from 6:00-7:30 a.m. EDT to discuss the mutCALR data.

Incyte (Nasdaq: INCY) has announced its upcoming participation at the Goldman Sachs Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025 at 11:20 am ET. Investors and interested parties can access the live webcast through Investor.Incyte.com, with the replay remaining available for 30 days following the presentation.

The FDA has approved Incyte's (NASDAQ: INCY) Zynyz® (retifanlimab-dlwr) as the first PD-1 inhibitor for advanced anal cancer treatment in the US. The approval covers two uses: first-line treatment in combination with chemotherapy for inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC), and as monotherapy for patients with disease progression on platinum-based chemotherapy. The Phase 3 trial showed a 37% reduction in progression/death risk, with median progression-free survival of 9.3 months vs 7.4 months for the placebo group. The treatment also demonstrated a 6.2-month improvement in median overall survival. In monotherapy, Zynyz achieved a 14% objective response rate and 49% disease control rate.

Incyte (INCY) has granted equity incentives to 60 new employees under its 2024 Inducement Stock Incentive Plan. The awards, effective May 1, 2025, include: Restricted Stock Units (RSUs): - 33,413 shares of common stock - Vest 25% annually over 4 years Stock Options: - 8,951 shares at $62.03 per share exercise price - 10-year term - 25% vests after first year - Remaining 75% vests monthly over 36 months The compensation committee approved these grants as employment inducements under Nasdaq Rule 5635(c)(4).

Incyte reports strong Q1 2025 financial results with total revenues reaching $1.05 billion, up 20% year-over-year. The company's flagship drug Jakafi achieved net product revenues of $709 million (+24% Y/Y), leading to increased 2025 guidance of $2.95-3.0 billion.

Key highlights: - Total product revenues: $922 million (+26% Y/Y) - Opzelura cream revenues: $119 million (+38% Y/Y) - New drug Niktimvo: $14 million in first two months of launch

Pipeline developments show promising results for povorcitinib in both hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The company continues advancing its innovative pipeline across multiple indications, including myeloproliferative neoplasms, GVHD, and various inflammatory conditions. Financial performance shows strong GAAP net income of $158.2 million with diluted EPS of $0.80.

Incyte (NASDAQ:INCY) has announced plans to present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago from April 25-30. The presentations will showcase research across multiple programs, including treatments for myeloproliferative neoplasms, ovarian cancer, and other solid tumors.

Key presentations include data on INCB177054, a novel DGKα/ζ dual inhibitor; INCA33890, a bispecific antibody targeting PD-1 and TGFβR2; and INCB057643, a BET protein inhibitor showing improvements in bone marrow function and effects on myelofibrosis treatment. The research demonstrates Incyte's ongoing efforts to advance its pipeline and transform cancer treatment approaches.